Even if an investor's planning to hold onto their shares for many years, it helps to start an investment off on the right foot. Seeing early stock price gains can help to cement confidence in a pick, which can give them the conviction that's needed to hold onto it during future downturns. So, today I'll be discussing a pair of healthcare stocks that have enough gas in the tank to make impressive gains in 2022. Both are heavily reliant on COVID-19 vaccine revenue at the moment, but neither is content to be a one-trick pony. Image source: Getty Images. 1. Pfizer Pfizer ( NYSE:PFE ) has (at least) two major revenue drivers that could power its share price higher: Its coronavirus vaccine, Comirnaty, and its new antiviral treatment for COVID-19, Paxlovid. That's on top of the myriad number of other moneymakers in its massive portfolio of drugs, of course. Investors are probably familiar with Comirnaty, which produced an estimated $36 billion in revenue for the company … [Read more...] about 2 Top Healthcare Stocks Ready for a Bull Run
Image source: The Motley Fool. Veeva Systems ( NYSE:VEEV ) Dec 01, 2021 , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, and thank you for standing by. Welcome to the Veeva Systems' fiscal 2022 third quarter results conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator instructions] I would now like to hand the conference over to Ato Garrett, senior director, investor relations. Please go ahead. This is the operator. Please stand by for technical assistance. Speakers, please hold. Ato Garrett -- Senior Director, Investor Relations Good afternoon, and welcome to Veeva's fiscal 2022 third quarter earnings conference call for the quarter ended October 31, 2021. As a reminder, we posted prepared remarks on Veeva's investor relations website just after 1 p.m. Pacific … [Read more...] about Veeva Systems (VEEV) Q3 2022 Earnings Call Transcript
Affecting one in 3,000 to 5,000 males worldwide, Duchenne muscular dystrophy (DMD) causes progressively worsening muscle weakness that eventually requires a wheelchair for most patients by age 11. Even worse, heart and lung complications often lead to mortality before age 30. Fortunately, Sarepta Therapeutics ( NASDAQ:SRPT ) has three approved RNAi therapies that can treat approximately 30% of the DMD population, and it's working on potentially curative gene therapies. Sales growth? Check. In the second quarter , the rare disease biotech raised full-year revenue guidance to between $565 million and $575 million, up from a prior range of $537 million to $547 million. Even more impressive than those 25% year-over-year revenue gains is its growth streak. After Sarepta's preliminary announcement of third-quarter results last week, the upcoming earnings report will mark an enviable 20th consecutive quarter of revenue growth. Image source: Getty Images. And the company … [Read more...] about Is This Beaten Down Biotech a Bad News Buy?
Women around the world are proving that 50 and beyond is the new golden age. Here are the founders, business and political leaders, scientists and vanguards leading the way throughout Europe, the Middle East and Africa. By Maggie McGrath With reporting by Nicola Slawson, Samantha Todd, Justin Conklin and Giacomo Tognini 66 | Managing Director, Easa Saleh Al Gurg Group | U.A.E Raja Al Gurg Businesswoman Al Gurg is the managing director and vice chair of the Easa Saleh Al Gurg Group, which is one of the largest conglomerates in the Middle East. Additionally, she is the Dubai Business Women Council president and board member of the Dubai Chamber of Commerce and Industry. In 2020, Al Gurg was awarded the Legion of Honor, Chevalier (Knight) by French President Emmanuel Macron for her efforts in strengthening the partnership between France and the U.A.E. 56 | Board Member, Al Jaber Group; Chair, Al Bashayer Investment Group | U.A.E Fatima Al … [Read more...] about 50 Over 50: EMEA 2022
Share to Twitter Share to Linkedin Bill O'Reilly, host of The O'Reilly Factor, has lost some of his biggest advertisers following news ... [+] of five settlements regarding sexual assault or inappropriate behavior. (Photo by Slaven Vlasic/Getty Images) Updated 4/8/2017, 11:45 a.m. Until only a few days ago, the word "invincible" was often associated with Fox News' ratings king Bill O'Reilly. Now, his future at the cable news network--his home since 1996--is much less certain. Sixty companies have pulled advertisements from O'Reilly's show following an April 1 report by the New York Times that detailed five settlements totaling $13 million made by him or Fox News in response to allegations of sexual harassment or other inappropriate behavior. (O'Reilly denies all allegations.) Just the day after the report came out, news emerged that despite these settlements, his $18.5 million contract was renewed. While the network may be … [Read more...] about Here Are All The Advertisers Who Have Dropped Bill O’Reilly
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here . T his week Forbes published another installment of its 50 Over 50 list, which highlights the women founders, politicians, business leaders and scientists leading the way throughout Europe, the Middle East and Africa. Leading the pack is Özlem Türeci, the 54-year-old cofounder and chief medical officer of German-based BioNTech, which developed the mRNA Covid-19 vaccine in partnership with Pfizer. Sarah Gilbert is another woman instrumental in the Covid-19 vaccine race. The 59-year-old vaccinologist at Oxford University is a co-inventor of the Oxford/AstraZeneca vaccine, for which she was recognized with a damehood and even had a Barbie doll made in her honor. Another pioneering scientist, Emmanuel Charpentier made the list for her work developing the gene editing technology Crispr. The 53-year-old microbiologist won the 2020 Nobel Prize in chemistry alongside Jennifer … [Read more...] about InnovationRx: 50 Over 50 EMEA; Plus, Reversing Vaccine Mandates